XCSport体育
About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
XCSport体育:Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
XCSport体育:Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
XCSport体育:Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
XCSport体育:Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
XCSport体育:Legal Statement
XCSport体育:Compliance
EN
简体
EN
繁體
Home
About Henlius
XCSport体育:Company Profile
XCSport体育:Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
XCSport体育:Products in R&D
XCSport体育:Clinical Trial
Science & Technology
XCSport体育:R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
XCSport体育:Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
Event
Popular Science
Media Reports
XCSport体育:Media Enquiry
Careers
XCSport体育:Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
XCSport体育:Contact Information
Customer Message
Privacy
XCSport体育:Legal Statement
XCSport体育:Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
XCSport体育:Popular Science
Highlights
Download
Media Reports
XCSport体育:Media Enquiry
2024-09-21
Henlius to Release the Preclinical Profiles of 2 ADC Programs at ESMO Congress 2023
2024-09-12
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA
2024-09-11
The Phase 3 Clinical Study Results of a Novel Anti-PD-1 mAb HANSIZHUANG for the First-Line Treatment of sqNSCLC Released at WCLC 2023
2024-08-28
Henlius and HanchorBio Enter into Strategic Collaboration to Spur Innovative Immunotherapies Development
2024-08-25
Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth
2024-08-17
Henlius Announces Upcoming Oral Presentation at WCLC 2023 Featuring Results for HANSIZHUANG from a Phase 3 MRCT in sqNSCLC
2024-07-27
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
2024-07-26
ruizhen.netpleted the phase 1/2 clinical trial of HLX04-O for the treatment of Ophthalmic Diseases
2024-07-17
Mr. Jason Zhu Succeeds as Chief Executive Officer and Mr. Wenjie Zhang Serves as Chairman of Henlius
1
2
3
4
5
6
...
8